A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-22 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Heroin-assisted treatment (HAT), or diamorphine-assisted treatment, refers to a type of Medication-Assisted Treatment (MAT) where semi-synthetic heroin is prescribed to opioid addicts who do not benefit from, or cannot tolerate, treatment with one of the established drugs used in opioid replacement therapy such as methadone or buprenorphine/naloxone (brand name Suboxone). For this group of patients, heroin-assisted treatment has proven superior in improving their social and health situation. Heroin-assisted treatment is fully a part of the national health system in Switzerland, Germany, the Netherlands, Canada, and Denmark. Additional trials are being carried out in the United Kingdom, Norway, and Belgium.
==== After effects ==== The after effects can be defined as any residual effects which may remain after the experience has reached its conclusion. After effects depend on the substance and usage. This is colloquially known as a "hangover" for negative after effects of substances, such as alcohol, cocaine, and MDMA or an "afterglow" for describing a typically positive, pleasant effect, typically found in substances such as cannabis, LSD in low to high doses, and ketamine.
== Signs and symptoms == Signs and symptoms of TIA are widely variable and can mimic other neurologic conditions, making the clinical context and physical exam crucial in ruling in or out the diagnosis. The most common presenting symptoms of TIA are focal neurologic deficits, which can include, but are not limited to:
Democracy Now! also broadcast a follow-up interview on May 12, 2009. This interview focused on reactions to the not-guilty verdict in the federal trial, where W. R. Grace and three former executives were acquitted on charges of knowingly exposing workers and townspeople to asbestos, and subsequently participating in a cover-up.
Sources: en.wikipedia.org
== Alternative medicine == With the growth of direct-to-consumer genetic testing, the alternative medicine industry has aggressively targeted a range of dubious tests and highly profitable quack treatments for claimed MTHFR polymorphisms, despite the lack of any demonstrated health effects of these mutations. The promotion of supplements and other treatments for MTHFR polymorphisms, especially centered on autistic spectrum disorder, have been characterised as "snake oil". Tests for MTHFR, while gaining popularity, are generally unnecessary because the association of MTHFR gene mutations with various diseases have not been established as clear-cut cause-and-effect relationship.
=== 1951–1953: DNA structure === In 1951 and 1952, together with William Cochran and Vladimir Vand, Crick assisted in the development of a mathematical theory of X-ray diffraction by a helical molecule. This theoretical result matched well with X-ray data for proteins that contain sequences of amino acids in the alpha helix conformation. Helical diffraction theory turned out to also be useful for understanding the structure of DNA. Late in 1951, Crick started working with James Watson at Cavendish Laboratory at the University of Cambridge, England. Using "Photo 51" (the X-ray diffraction results of Rosalind Franklin and her graduate student Raymond Gosling of King's College London, given to them by Gosling and Franklin's colleague Wilkins), Watson and Crick together developed a model for a helical structure of DNA, which they published in 1953. For this and subsequent work they were jointly awarded the Nobel Prize in Physiology or Medicine in 1962 with Wilkins. When Watson came to Cambridge, Crick was a 35-year-old graduate student (due to his work during WWII) and Watson was only 23, but had already obtained a PhD. They shared an interest in the fundamental problem of learning how genetic information might be stored in molecular form. Watson and Crick talked endlessly about DNA and the idea that it might be possible to guess a good molecular model of its structure. A key piece of experimentally-derived information came from X-ray diffraction images that had been obtained by Franklin, and Gosling.
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.
=== Potato Sack === The Potato Sack was an A.R.G (alternate reality game) conceived by Valve and 13 indie video game developers as a prelude to the release of Portal 2. Portal 2 had been announced by a similar game, where a patch applied to the Steam version of Portal in March 2010, provided clues heralding the official announcement. The Potato Sack game, launched on April 1, 2011, led to the reveal of "GLaDOS@home", a spoof of distributed computer challenges, to get players to cooperate on playing the independent games as to unlock Portal 2 on Steam about 10 hours before its planned release.
== Distribution == UCN III is widely distributed throughout the brain and is present in many bodily tissues—including the skin, gastrointestinal tract (GI tract), pancreatic beta cells, kidneys, heart, endocrine system, and brain. The medial amygdala (MeA), rostral perifornical area of the hypothalamus, bed nucleus of the stria terminalis (BNST), superior paraolivary nucleus, nucleus parabrachialis, and premammillary nucleus are the primary locations where UCN III is expressed. Expression of UCN III occurs late in the differentiation process of beta cells, where it is necessary for complete insulin secretion triggered by glucose and incretin, and is shown in mature beta cells in both mice and humans. Beta cells use the ATP-sensitive potassium channel (KATP channel) to facilitate the glucose-dependent release of UCN III. This is corroborated by the expression of PC1/3, Nkx6.1, and Pdx1 in hESC-derived UCN III + beta cells. But human UCN III is not specific to the beta cell lineage; rather, it is a generic marker for both the alpha and beta cell lineages, as seen by its expression in primary and hESC-derived alpha cells. A universal marker of alpha and beta cell development in humans is Ucn III. After triggering the receptors in the cerebral endothelial cells, UCN III crosses the blood–brain barrier, as demonstrated by a transneuronal tracer injection into the ventral pre-mammillary nucleus of the rat brain.
Sources: en.wikipedia.org
=== Amanda: Two Girls, One Cage === First aired: 18 November 2010 Meet Amanda, Bully Beatdown's first female bully with a bad attitude. She stands at 5'7 and makes life miserable for her victim, Keiko. Keiko is the second female victim to appear on the show, the first being Linda. Amanda calls herself "the queen" so Mayhem Miller brings in female MMA fighter Michelle Waterson who's done kickboxing since she was 10 years old to teach her a lesson. In the first round, she tapped out five times. In the second round, Amanda got KO'd with a brutal punch to her stomach. Keiko won $10,000 and an apology from Amanda.
The subarachnoid space is the space that normally exists between the arachnoid and the pia mater. It is filled with cerebrospinal fluid and continues down the spinal cord. Spaces are formed from openings at different points along the subarachnoid space; these are the subarachnoid cisterns, which are filled with cerebrospinal fluid. The dura mater is attached to the skull, whereas in the spinal cord, the dura mater is separated from the vertebrae by a space called the epidural space, which contains fat and blood vessels. The arachnoid is attached to the dura mater, while the pia mater is attached to the central nervous system tissue. If the dura mater and the arachnoid become separated due to injury or illness, the space between them is known as the subdural space. There is another potential space, the subpial space, between the pia mater and the glia limitans.
== Treatment == Because cachexia is a complex condition with several potential causes, treatment requires multiple approaches at the same time. The best strategy is to treat the cause of the cachexia, if known. For example, people with cachexia caused by AIDS often improve after starting treatment for AIDS. However, because the exact mechanism of cachexia is unclear, there is no single medication that can effectively treat it. Instead, treatment focuses on a combination of exercise, nutrition, medications like appetite stimulants and androgens like nandrolone decanoate, and psychosocial support.
As early researchers noted, the strychnine molecular structure, with its specific array of rings, stereocenters, and nitrogen functional groups, is a complex synthetic target, and has stimulated interest for that reason and for interest in the structure–activity relationships underlying its pharmacologic activities. An early synthetic chemist targeting strychnine, Robert Burns Woodward, quoted the chemist who determined its structure through chemical decomposition and related physical studies as saying that "for its molecular size it is the most complex organic substance known" (attributed to Sir Robert Robinson). The first total synthesis of strychnine was reported by the research group of R. B. Woodward in 1954, and is considered a classic in this field. The Woodward account published in 1954 was very brief (3 pages), but was followed by a 42-page report in 1963. The molecule has since received continuing wide attention in the years since for the challenges to synthetic organic strategy and tactics presented by its complexity; its synthesis has been targeted and its stereocontrolled preparation independently achieved by more than a dozen research groups since the first success.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.